The recent "controversy" involving Cristiano Ronaldo and Coca-Cola, one of the sponsors of the European football championship, sets the backdrop to explore the relationship between scientific research and private funding.
Neurological diseases have been a growing global problem before COVID-19 pandemic. Now they are further pushed by the consequences of post-COVID or long-COVID infections.
AIs in healthcare are constantly being deployed in new fields. The question is now: Will AIs end up replacing the physician?
Many underlying aetiologies and pathophysiological processes in paediatric critical illness differ from those in adults. The ERC 2021 Guidelines, devote an entire chapter to the topic.
This podcast surveys state-of-the-art presentations on clinical oncology findings on mCRPC, metastatic oesophageal squamous cell cancer, primary breast cancer, and more.
This EULAR 2021 correspondent's podcast revisits six congress state-of-the-art presentations on rheumatology topics, and research findings where the discipline overlapped with pediatrics, gastroenterology, and virology.
On 27 August 2021, it's that time again: The European Society of Cardiology (ESC) will come together online for its annual congress. A brief programme overview.
An Italian team has published a paper on the benefits of allowing ICU visits during a pandemic period, proposing essential policy and operational options for implementation.
COVID waves are finally calming down but conspiracy theorists have begun to insult history itself.
The ERC 2021 guidelines on post-resuscitation care contain major updates to the 2015 version on coronary angiography, blood pressure target, seizure treatment, temperature control, and other topics.
However well-intentioned physicians may be, they are often torn between incomprehension and a certain helplessness when dealing with precarious patients.
Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial.
In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time.
Adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell RCC.
Practice-oriented digitisation approaches can already be found in many areas of medicine. But does digitisation play a role in medical education? Survey results show: There is still a lot of catching up to do.
Adding abiraterone to ADT plus docetaxel significantly improves PFS in patients who present de novo mCSPC without meaningful added short-term toxicity according to phase 3 PEACE-1 trial.
Phase 3 RELATIVITY-047 trial results validate the efficacy of dual checkpoint blockade shown with the LAG-3 inhibitor relatlimab and nivolumab in advanced melanoma patients.
Analysis of phase 3 trials with atezolizumab in stage IV NSCLC patients shows longer overall survival for those experiencing immune-related AEs.
Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment.
Patritumab deruxtecan demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily pretreated, metastatic/locally advanced, EGFR-mutated NSCLC.